Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine’s AI-augmented platforms and close cooperation between Arvinas’ and Insilico Medicine’s scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery – PROTACs.
“Arvinas is the pioneer of PROTAC technology and a leader in protein degradation therapeutics. We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship,” said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.
In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August, it nominated the second preclinical candidate for kidney fibrosis.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
